BPC + GHK-Cu + TB-500 Triple Blend

Three compounds, one vial, and a copper atom with an open seat.

BPC + GHK-Cu + TB-500 Triple Blend is a research-use preparation supplying three compounds together: BPC-157 (GEPPPGKPADDAGLV, approximately 1419.5 Da), the acetylated thymosin beta-4 fragment TB-500 (Ac-LKKTETQ, approximately 889.0 Da), and the copper complex of the tripeptide glycine-histidine-lysine, whose 1:1 form has a molecular weight of 402.92 Da. No published study has evaluated the three compounds in combination in any species or model.

Three compounds, three different origins, one vial. BPC-157 is fifteen residues, GEPPPGKPADDAGLV, formula C62H98N16O22, molecular weight about 1419.5.

The sequence was identified inside a larger protein found in human gastric juice. TB-500 is seven residues, Ac-LKKTETQ, C38H68N10O14, about 889.0.

It is residues 17 through 23 of thymosin beta-4, roughly eighteen percent of that protein by mass. It is not thymosin beta-4 itself, whatever a label says. GHK is the odd one out, and it is also the one with a naming problem. Free GHK is the tripeptide glycine-histidine-lysine, C14H24N6O4, 340.38 daltons. Bind a copper and you get the 1:1 complex, C14H23CuN6O4 carrying a positive charge, 402.92 daltons. There is also a bis complex, one copper holding two GHK molecules, at 742.3. A vial that says GHK-Cu and stops there has not told you which of those three you are looking at, and those masses are far enough apart that the difference is not academic. So the honest starting point for a triple blend is this. Three compounds, one of them ambiguous by name alone, and no published work on the set.

Three separate mechanisms sharing a ride, with no study of the carpool.

Each of these has its own story, and none of those stories were written with the other two in the room. BPC-157 rodent work points at angiogenesis and VEGF signalling.

TB-500 binds actin through its LKKTET stretch, and actin is what cells use to crawl into damaged tissue. GHK-Cu gets studied as a copper carrier and for its effects on collagen expression in skin models.

Three separate literatures, none of them overlapping. What nobody covers is what happens when the three share a solution. Start by killing the lazy answer.

The concern you will see repeated is that copper oxidises methionine. Computed straight from the sequences, neither BPC-157 nor TB-500 contains a single methionine, cysteine, tryptophan, histidine or tyrosine. Not one oxidation-prone side chain between them.

That specific worry is fiction here and we would rather say so than let it sit. The real version is smaller and a lot more interesting. Copper's documented oxidation target in formulation work is histidine, and the only histidine anywhere in this vial belongs to GHK itself.

So the most likely copper chemistry in a triple blend is GHK-Cu going after GHK-Cu. Then there is the coordination question, which is the one nobody asks. Cu(II)GHK is not redox-silent.

Glutathione reduces it, and the published work reports the reduction rate being tuned by ternary ligands. In a closely analogous copper system, both binary complexes were redox-silent with ascorbate while a ternary complex could generate reactive oxygen species. The fifth seat is open, aspartate is one of the donors observed sitting in it, and BPC-157 shows up carrying two adjacent aspartates.

None of that is a result. It is a stack of documented facts pointing at an experiment nobody has run.

Each passenger has a file. The vehicle has none.

There is no study of this blend. That is the finding, and it belongs at the top rather than buried.

What does exist is one controlled test of two of the three. Bicer O, Adanir O, Guleryuz Y and colleagues, Jt Dis Relat Surg 2026;37(3):822-837, DOI 10.52312/jdrs.2026.2951, PMID 42542926.

Thirty-two male Sprague-Dawley rats, Achilles tendon transected and repaired, four groups of eight, intraperitoneal, four weeks. Verbatim: "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone." The authors suggest convergence on shared downstream pathways. Eight per group is small and they call the work exploratory, and the peptides were given as separate injections rather than mixed, so the paper says nothing about co-formulation.

On the chemistry side the citations are real, but they are about the parts and not about this product. Ufnalska and colleagues, Inorg Chem 2021, PMID 34781677, report glutathione reducing Cu(II)GHK with the rate tuned by ternary ligands. Mehr and colleagues, Acta Crystallogr D 2020, PMC7709198, describe residues including His, Asp and His/Pro from symmetry molecules completing copper's square-pyramidal coordination sphere in a GHK-tagged fusion protein.

Bossak-Ahmad and colleagues, PMC7503498, show GHK-Cu forming ternary complexes with a third ligand in solution. Mital and colleagues, Inorg Chem 2016, PMID 27409140, found a ternary copper complex able to generate reactive oxygen species where the binary complexes were silent. Nobody has connected any of that to this vial.

That connection is a hypothesis, and we are labelling it as one rather than selling it as a finding.

GHK-Cu without a stoichiometry is ambiguous. Free GHK is 340.38 daltons. The 1:1 copper complex is 402.92. The bis complex, one copper to two GHK, is 742.3. A label reading GHK-Cu and nothing else does not tell you which species is in the vial, and the gap between them is large.

A blend makes purity analysis harder, not easier. Purity methods get validated for one analyte. Three peptides plus a copper complex in one solution would need a method resolving every parent peak and every degradant, so a single combined percentage would not be analytically meaningful even in principle.

Status, said once. Research use only, not for human or veterinary use. WADA names BPC-157 under S0 for 2026 and covers thymosin beta-4 and its derivatives including TB-500 under S2.3. GHK-Cu is not listed by name, which is not the same thing as permitted, since S0 is a catch-all. Health Canada named all three compounds in its April 2026 advisory on peptides bought online, and all three sit in the FDA table of bulk drug substances nominated then withdrawn rather than on the 503A bulks list.